The Lancet November 07, 2026

Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial

Motovska Z, Hlinomaz O, Mrozek J, et al. (Senior Author: Bhatt DL)

Bottom Line

In patients with acute myocardial infarction complicated by cardiogenic shock, intravenous cangrelor achieved universal immediate platelet inhibition and significant 1-year improvements in left ventricular function compared to crushed ticagrelor, despite wide confidence intervals missing the 30-day non-inferiority clinical endpoint.

Key Findings

1. The primary laboratory endpoint (platelet reactivity index <50% at the end of primary PCI) was successfully achieved in 100% of the cangrelor group compared to 22.1% in the crushed ticagrelor group (p<0.0001).

2. The primary 30-day clinical composite endpoint (all-cause death, MI, or stroke) occurred in 37.6% of patients treated with cangrelor and 41.0% of patients receiving ticagrelor; however, this did not meet statistical significance for the prespecified non-inferiority margin (p=0.13).

3. Cangrelor provided superior protection against microvascular obstruction (MVO), resulting in a 73% lower risk of developing this complication compared to ticagrelor.

4. At 1-year follow-up, cangrelor patients demonstrated substantially greater recovery in left ventricular ejection fraction (LVEF), with a 37.9% improvement on ultrasound (vs 21.7% with ticagrelor) and a 15.8% increase on cardiac MRI (vs 2.1% with ticagrelor).

5. Major bleeding at 30 days was comparable between the two arms, occurring in 6.4% of the cangrelor group and 5.2% of the ticagrelor group.

Study Design

Design

RCT

Double-Blind

Sample

605

Patients

Duration

1 yr

Median

Setting

Multicenter

Population Patients presenting with acute myocardial infarction (AMI) complicated by cardiogenic shock who were undergoing primary percutaneous coronary intervention (PCI).

Intervention Intravenous cangrelor (administered as a 30 μg/kg IV bolus followed by a continuous infusion at 4 μg/kg).

Comparator Oral crushed ticagrelor (administered as a 180 mg loading dose followed by a maintenance dose of 90 mg twice daily).

Outcome Composite primary laboratory endpoint of platelet reactivity index <50% at the end of primary PCI, and primary clinical composite endpoint of all-cause death, myocardial infarction, or stroke at 30 days.

Study Limitations

• The failure to meet the prespecified non-inferiority margin for the 30-day clinical composite endpoint introduces statistical ambiguity into the clinical outcomes, rendering the robust imaging benefits hypothesis-generating.

• Assessing LVEF at 1 year in a cardiogenic shock cohort is inherently susceptible to survivor bias, as nearly half of these patients typically succumb to the condition within the first year.

• Cardiac MRI and echocardiography in acutely unstable cardiogenic shock patients often suffer from missing data if patients are too hemodynamically fragile to undergo scanning.

Clinical Significance

DAPT-SHOCK-AMI highlights the severe pharmacokinetic limitations of oral P2Y12 inhibitors in cardiogenic shock. Because splanchnic hypoperfusion drastically impairs enteral drug absorption, even crushed ticagrelor failed to achieve adequate platelet inhibition in nearly 80% of patients at the end of PCI. Intravenous cangrelor bypassed this physiological barrier, resulting in 100% effective platelet inhibition. While the primary 30-day clinical outcomes narrowly missed formal non-inferiority bounds, cangrelor dramatically reduced microvascular obstruction and yielded profound, sustained improvements in myocardial function at 1 year, offering a vital therapeutic strategy to mitigate the progression to long-term heart failure in shock survivors.

Historical Context

Historically, dual antiplatelet therapy for STEMI relies on potent oral agents. However, patients with cardiogenic shock exhibit delayed gastric emptying, splanchnic vasoconstriction, and a heavy reliance on vasopressors, heavily blunting the absorption and bioactivation of oral drugs. Prior registries and observational data highlighted alarming delays in platelet inhibition for shock patients, leaving the microvasculature vulnerable during stent deployment. DAPT-SHOCK-AMI is a landmark trial as the first randomized, double-blind study to directly compare an intravenous P2Y12 inhibitor against the most aggressive oral strategy (crushed ticagrelor) exclusively within a cardiogenic shock population, cementing the mechanistic superiority of parenteral therapy in this critical setting.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why might an intravenous P2Y12 inhibitor like cangrelor be theoretically superior to enterally administered crushed ticagrelor in a patient presenting with acute myocardial infarction complicated by cardiogenic shock?

Key Response

In cardiogenic shock, systemic hypoperfusion leads to splanchnic vasoconstriction, severely impairing gastrointestinal motility and enteral drug absorption. Cangrelor, being an intravenous agent, bypasses the gut to provide immediate and predictable platelet inhibition, whereas even crushed ticagrelor may have a significantly delayed onset of action in shock states.

Resident

Given that DAPT-SHOCK-AMI showed universal immediate platelet inhibition with cangrelor but missed its 30-day non-inferiority clinical endpoint, how should this influence your choice of P2Y12 inhibitor when stabilizing an intubated patient with AMI and cardiogenic shock in the cardiac ICU?

Key Response

Residents must weigh pharmacodynamic superiority against unproven short-term clinical benefit. While cangrelor guarantees platelet inhibition in shock which is highly useful during urgent PCI, the lack of clear 30-day clinical superiority means crushed ticagrelor remains a viable option. The decision should factor in bleeding risk, GI function, the potential need for rapid offset if CABG is required, and institutional pharmacy protocols.

Fellow

The trial demonstrated a significant improvement in left ventricular function at 1 year with cangrelor despite failing to meet the 30-day non-inferiority clinical endpoint. What are the potential pathophysiological mechanisms by which a short-acting intravenous antiplatelet agent could favorably influence long-term ventricular remodeling in cardiogenic shock?

Key Response

Fellows should explore microvascular physiology. Immediate, potent platelet inhibition with cangrelor during primary PCI may better prevent distal microvascular embolization and the no-reflow phenomenon compared to delayed enteral absorption. This preserves microcirculatory integrity, potentially limiting infarct size and adverse remodeling, which manifests as improved LV function at 1 year despite wide confidence intervals for early macro-clinical events.

Attending

As an attending directing a cardiac catheterization laboratory, how do you justify the transition to cangrelor as the default strategy for AMI-CS patients based on DAPT-SHOCK-AMI, considering its high cost and the trial failing to definitively meet the 30-day clinical endpoint?

Key Response

Attendings must balance clinical efficacy, resource allocation, and systems-based practice. The justification hinges on viewing AMI-CS as a state of profound enteral failure where guaranteeing antiplatelet effect during PCI is paramount to preventing acute stent thrombosis. The 1-year LV function data provides a downstream value proposition in reduced heart failure burden that may offset the upfront drug cost.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The trial failed to meet the 30-day non-inferiority clinical endpoint due to wide confidence intervals. In the context of conducting randomized trials in highly lethal conditions like cardiogenic shock, how does the estimation of event rates and non-inferiority margins compromise statistical power, and what alternative trial designs could better evaluate efficacy?

Key Response

Shock trials often suffer from lower-than-expected enrollment and highly variable baseline mortality, inflating variance. A non-inferiority design is risky because wide confidence intervals driven by high data noise easily cross the margin. Researchers might suggest adaptive designs, Bayesian approaches, or hierarchical composite endpoints like the win ratio to better capture treatment effects without requiring prohibitive sample sizes.

Journal Editor

As a peer reviewer assessing the DAPT-SHOCK-AMI manuscript, what are the primary methodological concerns regarding the use of a double-blind, double-dummy design comparing an IV infusion to crushed enteral pills in mechanically ventilated shock patients, and how might missing data affect the 1-year secondary endpoints?

Key Response

A double-dummy design in shock is complex; administering placebo IV and placebo crushed pills via NG tube requires meticulous coordination. Reviewers must scrutinize whether blinding was truly maintained, if delays in NG tube placement disadvantaged the ticagrelor group, and if survivorship bias or loss to follow-up over 1 year disproportionately skewed the LV function outcomes in this high-mortality cohort.

Guideline Committee

Current ACC and ESC guidelines offer limited specific guidance on the preferred route of P2Y12 administration in cardiogenic shock. Based on the DAPT-SHOCK-AMI findings, should future guidelines upgrade the recommendation for intravenous P2Y12 inhibitors in AMI-CS, and what level of evidence would this constitute?

Key Response

Guidelines acknowledge delayed absorption in shock and mention cangrelor as a Class IIb option. Given this trial showed pharmacodynamic superiority and 1-year LV benefits but missed the primary 30-day clinical non-inferiority endpoint, the committee would likely issue a Class IIa recommendation, Level of Evidence B-R, for cangrelor in AMI-CS to ensure rapid platelet inhibition, rather than a Class I mandate.

Clinical Landscape

Noteworthy Related Trials

2013

CHAMPION PHOENIX Trial

n = 10,942 · NEJM

Tested

Intravenous cangrelor

Population

Patients undergoing elective or urgent PCI

Comparator

Oral clopidogrel

Endpoint

Composite of death, MI, ischemia-driven revascularization, or stent thrombosis at 48 hours

Key result: Cangrelor significantly reduced the rate of ischemic events during PCI compared with clopidogrel, with no significant increase in severe bleeding.

2017

CULPRIT-SHOCK Trial

n = 706 · NEJM

Tested

Culprit-lesion-only PCI

Population

Patients with multivessel disease, AMI, and cardiogenic shock

Comparator

Multivessel PCI

Endpoint

30-day composite of death or severe renal failure leading to renal-replacement therapy

Key result: Culprit-lesion-only PCI significantly reduced the 30-day risk of the composite endpoint compared to immediate multivessel PCI.

2019

ISAR-REACT 5 Trial

n = 4,018 · NEJM

Tested

Prasugrel

Population

Patients with acute coronary syndromes scheduled for invasive evaluation

Comparator

Ticagrelor

Endpoint

Composite of death, myocardial infarction, or stroke at 1 year

Key result: Prasugrel significantly reduced the incidence of the primary endpoint compared to ticagrelor without increasing major bleeding.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis